drugset / Trial / NCT01159873
Single Ascending-Dose Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study to Characterize the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-37251 in Healthy Postmenopausal Women.
Timeline
- Start
- 2010-07
- Primary completion
- 2010-10
- Completion
- 2010-10
Outcome
Outcome not reported
Stopped (Business): “Study has been stopped by sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CEP-37251 | Unknown | 0.03 mg/kg | Subcutaneous |
| Subject | CEP-37251 | Unknown | 0.1 mg/kg | Subcutaneous |
| Subject | CEP-37251 | Unknown | 0.3 mg/kg | Subcutaneous |
| Subject | CEP-37251 | Unknown | 1 mg/kg | Subcutaneous |
| Subject | CEP-37251 | Unknown | 3 mg/kg | Subcutaneous |